The latest Business updates from the science industry
Collaboration to Develop Tumour Progression Regulator Leads by Heather Hobbs
UK-based biopharmaceutical company Phoremost and AI driven pharmatech XtalPi, have signed an agreement to identify and develop compounds to advance a drug discovery program against targets that epigenetically regulate tumour progression and which have been previously classifi ed as ‘undruggable’. The companies will pursue this challenging goal with a unique combination of machine learning and physics-based computation methods, using XtalPi’s intelligent digital drug discovery and development (ID4) platform, to explore novel sites discovered by PhoreMost’s SITESEEKER® platform.
“XtalPi’s AI-based ID4 and PhoreMost’s SITESEEKER are highly complementary platforms, and we look forward to working together with the team. This alliance marks an exciting chapter in PhoreMost’s development, as we now seek to rapidly progress our internal portfolio of novel fi rst-in-class targets into drug discovery,” said Phoremost CEO Dr Chris Torrance.
“Today, many diseases lack effective treatment because their corresponding targets are too challenging for traditional drug discovery methods.,” added Dr Jian Ma, co-founder and CEO of XtalPi. “We are excited to combine PhoreMost’s target discovery technology with our ability to quickly identify lead compounds with desirable drug properties, and continuously translate high-quality ‘undruggable’ targets into fi rst- in-class pipeline assets to address unmet medical needs.
More information online:
ilmt.co/PL/pOaL 53440pr@reply-direct.com
Jian Ma CEO XtalPi Phoremost CEO Chris Torrance
Agreement to Advance Preclinical Services
Key Appointments to drive International Business Strategy
Cell culture company CN BIO has appointed James Craven as Chief Commercial Offi cer and Dr Brian Manning as US Head of Sales. Dr Sarah Payne has also joined the company as Product Marketing Manager. Following the completion of a USD$9 million USD funding round in February, the appointments will help drive CN Bio’s sales and business strategy, with a focus on further developing its US customer base.
James joins CN Bio from Brooks Life Sciences, where he was formerly Director of Market Strategy and Commercial Delivery. He has also held senior management positions at TTP Labtech and Titian Software. As CN Bio’s CCO, he will expand the company’s visibility and drive sales of products and services.
Eric Rhodes
US Biotech Applied StemCell, has signed a licencing agreement with Dublin-based ERS Genomics for use of its CRISPR/Cas9 intellectual property (IP) co-owned by Dr Emmanuelle Charpentier, for developing its preclinical research tools, including cell and animal model generation, antibody discovery and preclinical assay services to support cell and gene product development.
“Applied StemCell has been a leading stem cell company I have followed for many years,” said Eric Rhodes, CEO of ERS Genomics. “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing.”
“We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” added Ruby Tsai, CEO of Applied StemCell.
Financial details of the agreement were not disclosed. More information online:
ilmt.co/PL/QL9J
53446pr@reply-direct.com
Brian has signifi cant business development experience across the pharma and biotech industries in the US, Europe and Asia; previously Senior Director of Business Development at InSphero, he has held key positions at Pfi zer, DiscoverX, GenScript, and Cyclofl uidic, where he was Vice President of Business Development in North America. He will be responsible for cultivating CN Bio’s commercial and scientifi c relationships and applications support on a global basis.
Sarah will oversee sales, product management and marketing to shape the company’s expanding technology portfolio in all application areas. Sarah has previously held senior marketing roles at leading life science companies, including SPT Labtech, most recently, and GE Healthcare.
James Craven, Chief Commercial Offi cer, CN Bio, commented: “As an established and trusted cell culture company, already working with over eight of the top 20 pharma companies globally, I’m enthusiastic to be part of CN Bio’s team, to build its strategic partnerships and ensure we continue to provide the best support to researchers. Brian, Sarah and I have signifi cant subject matter experience, all with strong scientifi c backgrounds, which is essential when joining such a credible team, driven by technical expertise and depth of knowledge.”
More information online:
ilmt.co/PL/ZXAv 53441pr@reply-direct.com
BIOX Specialist Joins Biomarker-based Diagnostics Group
Beogenomics, a specialised software developer in Bioinformatics and Artifi cial Intelligence (BIOX) has been acquired by APIS Assay Technologies Ltd, a company combining in vitro diagnostics (IVD) experience with integrated AI to develop biomarker-based diagnostic assays.
Start-up Beogenomics which has been developing both on-prem and secure cloud-based data analysis solutions to help design, build and run custom tailored genomics & proteomics pipelines, will be integrated into Manchester-based APIS, supporting the launch of a new BIOX Service Line that can deliver added value to customers.
Dr Joachim Schorr, CEO of APIS, said: “We are delighted to announce
our acquisition of Beogenomics, which offers strong operational and cultural fi ts. We look forward to welcoming the talented team and working together to expand our BIOX capacity internally, and build out a new, discrete, and externally-facing service line.”
“With the addition of Beogenomics’ proven expertise in bioinformatics – APIS can more effectively capture the exciting opportunities presented in the bioinformatics space,” added Ian Kavanagh, COO of APIS.
More information online:
ilmt.co/PL/kJg0 53445pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
